These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24806821)

  • 1. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
    Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
    Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
    Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
    Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
    Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
    Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
    Doran AC; Osgood SM; Mancuso JY; Shaffer CL
    Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X; Cheong J; Ding X; Deshmukh G
    Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
    Sato S; Matsumiya K; Tohyama K; Kosugi Y
    AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
    Fridén M; Winiwarter S; Jerndal G; Bengtsson O; Wan H; Bredberg U; Hammarlund-Udenaes M; Antonsson M
    J Med Chem; 2009 Oct; 52(20):6233-43. PubMed ID: 19764786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid.
    Liu X; Van Natta K; Yeo H; Vilenski O; Weller PE; Worboys PD; Monshouwer M
    Drug Metab Dispos; 2009 Apr; 37(4):787-93. PubMed ID: 19116265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats.
    Chen C; Zhou H; Guan C; Zhang H; Li Y; Jiang X; Dong Z; Tao Y; Du J; Wang S; Zhang T; Du N; Guo J; Wu Y; Song Z; Luan H; Wang Y; Du H; Zhang S; Li C; Chang H; Wang T
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00575. PubMed ID: 32266794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
    Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
    Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
    Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
    Westerhout J; Smeets J; Danhof M; de Lange EC
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF as a surrogate for assessing CNS exposure: an industrial perspective.
    Lin JH
    Curr Drug Metab; 2008 Jan; 9(1):46-59. PubMed ID: 18220571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.